Newswire (Published: Monday, June 17, 2019, Received: Monday, June 17, 2019, 7:23:07 PM CDT)

Word Count: 443

2019 JUN 17 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Daily -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting out of Madrid, Spain, by NewsRx editors, research stated, “Germline and somatic aberrations in DNA damage repair (DDR) genes are more prevalent in prostate cancer than previously recognized, with BRCA2 as the most commonly altered gene. Germline mutations in BRCA2 have been linked to poor prognosis when patients are managed under the protocols currently approved for prostate cancer.”

Funders for this research include Instituto de Salud Carlos III, European Association of Urology Research Foundation, Department of Defense Award, Fundacion BBVA, CERCA Program/Generalitat de Catalunya, FEDER funds/European Regional Development Fund (ERDF)-A Way to Build Europe, Ministerio de Economia y Empresa, Young Investigator Awards from the Prostate Cancer Foundation, Department of Defense US.

Our news journalists obtained a quote from the research from Spanish National Cancer Research Center, “The impact of germline mutations in other DDR genes beyond BRCA2 remain unclear. Importantly, a quarter of prostate cancer patients identified as germline mutation carriers lack a family history of cancer. The clinical implications of somatic DDR defects are yet to be elucidated. Poly ADP-ribose polymerase (PARP) inhibitors and platinum-based chemotherapy have proven to be effective in the treatment of other tumor types linked to BRCA1 and BRCA2 alterations and several trials are currently evaluating their efficacy in prostate cancer.”

According to the news editors, the research concluded: “Here, we summarize the available evidence regarding the prevalence of somatic and germline DDR defects in prostate cancer; their association with clinical outcomes; the trials assessing the efficacy of new therapies that exploit DDR defects in prostate cancer and briefly discuss some uncertainties about the most appropriate management for these patients.”

For more information on this research see: Brca2 and Other Ddr Genes In Prostate Cancer. CANCERS, 2019;11(3):. CANCERS can be contacted at: Mdpi, St Alban-Anlage 66, Ch-4052 Basel, Switzerland.

Our news journalists report that additional information may be obtained by contacting E. Castro, Spanish National Cancer Research Center, Prostate Canc Clin Res Unit, Madrid 28029, Spain. Additional authors for this research include P. Nombela, R. Lozano, D. Olmos, A. Aytes and J. Mateo.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.3390/cancers11030352. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Places

Southern Europe
Western Europe
Switzerland
Spain
Europe
Province of Madrid
Basel
Madrid

Subjects

Science and Technology
      Scientific Research
            Medical Research
                  Clinical Outcomes
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Genetics
            Medical Research
                  Clinical Outcomes
      Medical Specialties and Practices
            Urology
Politics and Government
      Government Agencies (U.S.)
            Department of Defense